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Celebrating the decline in syphilis in pregnancy: a sobering 
reminder of what’s left to do
In 2015, Cuba became the ﬁ rst country to be validated 
by WHO for having achieved the elimination of mother-
to-child transmission of HIV and syphilis.1 In June, 2016, 
Thailand, Armenia, Belarus, and Moldova were also 
validated.2 This is amazing news, which demonstrates 
that, given the political will, a policy for eﬀ ective 
prenatal screening and treatment, and a commitment 
to implement that policy at every level of the health-
care system, countries with limited resources can now 
have an HIV and syphilis free generation.
The paper by Saman Wijesooriya and colleagues in 
The Lancet Global Health3 reports on progress towards the 
elimination of congenital syphilis between 2008 and 
2012. The good news from this report is that maternal 
syphilis infections are estimated to have decreased 
by 38% and adverse pregnancy outcomes by 39% 
during this time. The reduction was greatest in Asia, 
with India alone accounting for 66% of the reduction 
in maternal infections and 64% of the reduction in 
adverse outcomes. The proportion of pregnant women 
not tested for syphilis in antenatal care declined in 
all regions except Africa (49·0%) and the Eastern 
Mediterranean region (18·6%).
However, the reality is that, despite this progress, 
nearly 1 million pregnant women had syphilis, and 
approximately 350 000 had a syphilis-induced adverse 
pregnancy outcome in 2012. The fact that 49% of 
pregnant women in the African region are still not 
being tested for syphilis is an additional cause for 
concern. Most syphilis-induced pregnancy outcomes 
were in women who attended antenatal care, 
suggesting that these poor outcomes could have been 
prevented. What are the reasons for this, and how can 
they be addressed?
Prenatal syphilis screening has long been recognised 
as one of the most cost-eﬀ ective health interventions 
available,4 yet access to screening was poor in many 
countries, and many women who tested positive 
were not treated because they did not return for their 
results. Adverse pregnancy outcomes due to syphilis 
can be prevented with a single dose of benzathine 
penicillin given before 28 weeks’ gestation, making 
the treatment of maternal syphilis much cheaper 
and simpler than the prevention of mother-to-child 
transmission (PMTCT) of HIV.5
In 2004, at a time when PMTCT programmes for HIV 
were being introduced and scaled up in many countries, 
it seemed that syphilis had been forgotten,6 despite 
being responsible for more than 500 000 perinatal 
deaths annually. At this time, rapid, point-of-care 
syphilis tests became available that fulﬁ lled the ASSURED 
criteria—ie, aﬀ ordable, sensitive, speciﬁ c, user-friendly, 
robust and reliable, equipment-free, and deliverable to 
those in need.7 These tests have been rolled out in many 
countries, greatly increasing access to screening and 
enabling treatment to be given immediately.8 In 2007, 
WHO launched a global initiative for the elimination of 
mother-to-child transmission of syphilis,9 and in 2008 
WHO and global partners introduced surveillance of 
syphilis in pregnancy within the HIV Universal Access 
and Global AIDS Response Progress Reporting System. 
Countries were encouraged to report data on three core 
indicators on antenatal care attendees: syphilis testing, 
seroprevalence, and treatment coverage.
UNAIDS published data on the Global Plan towards 
the elimination of new HIV infections among children 
by 2015 in 21 countries where 90% of women with 
HIV lived.10 Between 2009 and 2015, mother-to-child 
transmission rates of HIV were reduced by 86% in 
Uganda, 84% in South Africa, 84% in Burundi, 80% 
in Swaziland, 79% in Namibia, 75% in Mozambique, 
and 71% in Malawi. With the lack of progress in syphilis 
screening in Africa reported by Wijesooriya and 
colleagues, we are once more faced with the tragic reality 
that many of these babies may have avoided HIV but died 
from syphilis.6 How can we address the huge disparity 
between PMTCT programmes for HIV and syphilis?
We need to tackle this from several fronts. First, 
political commitment. Lack of political commitment 
results in lack of funding and human resources for 
prenatal syphilis screening programmes. Although 
PMTCT programmes for HIV are well established in most 
countries, syphilis screening programmes suﬀ er from 
neglect and under funding. According to The Lancet’s 
Stillbirth Series,11 syphilis is among the top causes of 
preventable stillbirths, adding weight to the investment 
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case for congenital syphilis elimination as part of the 
response to end preventable stillbirths by 2030.
Second, we have technological solutions that make 
it possible to combine screening for HIV and syphilis 
within existing PMTCT programmes for HIV. It is now 
possible to test for both HIV and syphilis from a single 
drop of blood and have the result in 15–20 min. These 
tests are commercially available, and one is prequaliﬁ ed 
by WHO.12 Leveraging funds and well established 
infra structure set up for HIV PMTCT programmes 
to eliminate congenital syphilis is possible if these 
technological solutions are widely adopted.
Finally, the lessons learnt from countries that have 
achieved elimination should be widely shared. 
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